Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 1 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. WO 2026115454

    ANTICORPS ANTI-CLAUDINE 18.2, FRAGMENTS DE LIAISON À L'ANTIGÈNE ET CONJUGUÉS ANTICORPS-MÉDICAMENT ASSOCIÉS ET MÉTHODES D'UTILISATION DANS UNE THÉRAPIE ANTICANCÉREUSE

    ASTRAZENECA AB [SE] · Granted Jun 4, 2026 · Expires May 30, 2046

    granted
  2. US 20260144885

    ANTI-LRRC15 ANTIBODIES AND USES THEREOF

    BRISTOL MYERS SQUIBB CO [US] · Granted May 28, 2026 · Expires May 23, 2046

    granted
  3. US 20260144884

    ANTI-LRRC15 ANTIBODY DRUG CONJUGATES

    BRISTOL MYERS SQUIBB CO [US] · Granted May 28, 2026 · Expires May 23, 2046

    granted
  4. WO 2026107136

    CONJUGUÉS ANTICORPS ANTI-CEACAM5-MÉDICAMENT POUR LE TRAITEMENT DU CANCER

    BRISTOL MYERS SQUIBB CO [US] · Granted May 21, 2026 · Expires May 16, 2046

    granted
  5. WO 2026107143

    COMBINAISON DE DOSES FIXES D'ANTICORPS ANTI-FUCOSYL-GM1 ET D'ANTICORPS ANTI-PD-1 ET SES UTILISATIONS

    BRISTOL MYERS SQUIBB CO [US] · Granted May 21, 2026 · Expires May 16, 2046

    granted
  6. US 20260115307

    ANTI-FUCOSYL-GM1 ANTIBODY DRUG CONJUGATES

    BRISTOL MYERS SQUIBB CO [US] · Granted Apr 30, 2026 · Expires Apr 25, 2046

    granted
  7. WO 2026075950

    SCHÉMA POSOLOGIQUE POUR AGENT ANTI-DLL3

    AMGEN INC [US] · Granted Apr 9, 2026 · Expires Apr 4, 2046

    granted
  8. WO 2026057739

    POLYTHÉRAPIE COMPRENANT DES ANTICORPS ANTI-CTLA4 ET DES ANTICORPS ANTI-PD-1 POUR LE TRAITEMENT DU CANCER DE L'OVAIRE RÉSISTANT AU PLATINE

    BIONTECH SE [DE] · Granted Mar 19, 2026 · Expires Mar 14, 2046

    granted
  9. WO 2026060304

    ADMINISTRATION SOUS-CUTANÉE D'UN AGENT ANTI-DLL3 POUR LE TRAITEMENT DU CANCER

    AMGEN INC [US] · Granted Mar 19, 2026 · Expires Mar 14, 2046

    granted
  10. WO 2026052764

    PROCÉDÉ DE NOTATION POUR UNE THÉRAPIE PAR CONJUGUÉ ANTICORPS ANTI-TROP2-MÉDICAMENT

    ASTRAZENECA UK LTD [GB] · Granted Mar 12, 2026 · Expires Mar 7, 2046

    granted
  11. WO 2026042803

    UTILISATION D'UN ANTICORPS BISPÉCIFIQUE ANTI-CLDN4/ANTI-CD137 EN COMBINAISON AVEC UN MÉDICAMENT À BASE DE PLATINE POUR LE TRAITEMENT DU CANCER

    ASTELLAS PHARMA INC [JP] · Granted Feb 26, 2026 · Expires Feb 21, 2046

    granted
  12. WO 2026041780

    POLYTHÉRAPIE COMPRENANT DES ANTICORPS ANTI-CTLA4 ET UNE CHIMIOTHÉRAPIE POUR LE TRAITEMENT DU CANCER

    BIONTECH SE [DE] · Granted Feb 26, 2026 · Expires Feb 21, 2046

    granted
  13. US 20260035439

    Anti-Sars-COV-2 Antibodies and Uses Thereof

    ABBVIE INC [US] · Granted Feb 5, 2026 · Expires Jan 31, 2046

    granted
  14. EP 4670742

    ANTI-CD79B-ANTIKÖRPER-WIRKSTOFFKONJUGATE

    ABBVIE INC [US] · Granted Dec 31, 2025 · Expires Dec 26, 2045

    granted
  15. WO 2025265012

    COMPOSITIONS COMPRENANT DES ANTICORPS ANTI-PCSK9

    AMGEN INC [US] · Granted Dec 26, 2025 · Expires Dec 21, 2045

    granted
  16. WO 2025261951

    POLYTHÉRAPIE AVEC UN ANTICORPS ANTI-CA19-9 ET DU FOLFIRINOX DANS LE TRAITEMENT DU CANCER

    BIONTECH SE [DE] · Granted Dec 26, 2025 · Expires Dec 21, 2045

    granted
  17. AU 2024276234

    METHODS OF TREATMENT USING ANTI-C-MET ANTIBODY DRUG CONJUGATES

    ABBVIE MFG MANAGEMENT UNLIMITED COMPANY [IE] · Granted Dec 4, 2025 · Expires Nov 29, 2045

    granted
  18. US 2025325692

    METHODS OF TREATMENT USING ANTI-SEZ6 ANTIBODY DRUG CONJUGATES

    ABBVIE INC [US] · Granted Oct 23, 2025 · Expires Oct 18, 2045

    granted
  19. WO 2025207932

    CAPSIDES DE VAA COMPRENANT DES DOMAINES D'ANTICORPS ANTI-TRANSFERRINE

    BIOGEN MA INC [US] · Granted Oct 2, 2025 · Expires Sep 27, 2045

    granted
  20. WO 2025207959

    ANTICORPS ANTI-RÉCEPTEURS DE LA TRANSFERRINE ET LEURS UTILISATIONS

    BIOGEN MA INC [US] · Granted Oct 2, 2025 · Expires Sep 27, 2045

    granted
  21. US 12428487

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  22. US 12427173

    Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies

    Biomed Valley Discoveries, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  23. US 12427201

    Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates

    Sutro Biopharma, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  24. US 12428480

    Anti-CD19 antibodies and multi-specific binding proteins

    Cullinan Therapeutics, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted